tradingkey.logo

Biontech SE

BNTX
查看詳細走勢圖
106.620USD
+1.080+1.02%
收盤 02/06, 16:00美東報價延遲15分鐘
25.64B總市值
虧損本益比TTM

Biontech SE

106.620
+1.080+1.02%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.02%

5天

-6.27%

1月

+8.70%

6月

-4.20%

今年開始到現在

+12.00%

1年

-11.11%

查看詳細走勢圖

TradingKey Biontech SE股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Biontech SE當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名52/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為138.01。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Biontech SE評分

相關信息

行業排名
52 / 392
全市場排名
160 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Biontech SE亮點

亮點風險
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
業績轉虧
公司業績轉虧,最新年度虧損美元
估值低估
公司最新PE估值-52.40,處於3年歷史低位
機構減倉
最新機構持股54.72M股,環比減少0.02%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉66.49K股

分析師目標

基於 22 分析師
買入
評級
138.005
目標均價
+30.76%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Biontech SE新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Biontech SE簡介

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
公司代碼BNTX
公司Biontech SE
CEOSahin (Ugur)
網址https://www.biontech.com/
KeyAI